Trump’s Drug Price Promises: Bold Talk, Limited Results

Donald Trump has been loud and proud about cutting prescription drug prices. From campaign pledges to executive orders, he’s painted a picture of Americans paying far less for their medicine—sometimes claiming reductions of up to 80%. So, what actually happened?

Let’s start with the history. In 2018, his administration launched the American Patients First blueprint, promising immediate relief: generic approval fast-tracked, rebates restructured, and public dashboards showing drug prices. HHS boasted early wins—15 companies froze or rolled back prices within 100 days.

Then came a flurry of executive orders: an April 15, 2025 directive aimed at boosting generics, easing drug importation, and lowering middleman fees, followed by a May 12 Most-Favored-Nation (MFN) order promising U.S. prices match the lowest in other advanced nations. Trump claimed these moves would end the U.S. “free ride” on global drug costs.

Here’s where reality bites. The 2018 blueprint sparked short-lived price freezes from some companies, but there’s no evidence of broad, sustained drops. Experts say the real savings were modest and temporary. The April and May 2025 orders laid out ambitious goals—but relied on voluntary compliance, rulemaking delays, and faced certain legal challenges. Drug industry lobbyists, like PhRMA, warned these moves could hurt innovation and weren't actionable without Congress—especially because previous MFN attempts were blocked by courts.

To sum it up? Trump made big promises and took executive action. But so far: no sweeping drug price cuts. Without congressional backing—especially enabling Medicare negotiation—these efforts are more talk than triumph.

Mechanisms are in place. Signals have been sent. But until drug prices really drop—not just in headlines—this feels like a campaign promise hanging in the balance.

Works Cited

“American Patients First.” HHS.gov, www.hhs.gov/sites/default/files/AmericanPatientsFirst.pdf. Accessed 8 July 2025.

“Report on 100 Days of Action on the American Patient First Blueprint.” HHS.gov, www.hhs.gov/sites/default/files/ReportOn100DaysofAction_AmericanPatientsFirstBlueprint.pdf. Accessed 8 July 2025.

Turow, Rachel, and Avia M. Dunn. “Trump Attempts to Rein In Drug Prices With Most‑Favored‑Nation Approach.” Skadden, 13 May 2025, www.skadden.com/insights/publications/2025/05/trump-attempts-to-rein-in-drug-prices-with-most-favored-nation-approach.

“Fact Sheet: President Donald J. Trump Announces Actions to Put American Patients First.” White House, 12 May 2025, www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/.

“Most‑Favored‑Nation Drug Pricing in the U.S.” Wikipedia, 2025, en.wikipedia.org/wiki/Most_Favored_Nation_Drug_Pricing. Accessed 8 July 2025.

Ohlen, Elsa. “Trump Wants Cheaper Drugs Like Europe Has. How It Works.” Barron’s, 12 June 2025.

Gardner, Jonathan, and Ned Pagliarulo. “Trump Revives ‘Most Favored Nation’ Plan in Effort to Cut U.S. Drug Prices.” BioPharma Dive, 12 May 2025.